The strong results and positive guidance suggest Merit Medical is executing well on its growth strategy. Traders should monitor the company's ability to maintain margin expansion and revenue growth, particularly in the endoscopy segment. The 6-8% revenue growth guidance for 2026 provides a clear target to evaluate future performance against.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $79.23entry
- T+1 · 9mo ago −1.53%α −0.98% · $78.02
- T+5 · 9mo ago −6.40%α −5.30% · $74.16
- T+20 · 8mo ago −14.04%α −8.80% · $68.11
- T+60 · 6mo ago −18.60%α −25.55% · $64.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Merit Medical reported strong fourth quarter and full year 2025 results, with revenue of $393.9 million (up 11% YoY) and $1.516 billion (up 12% YoY), driven by growth in cardiovascular and endoscopy segments. The company also issued fiscal year 2026 guidance, projecting revenue of $1.610-$1.630 billion (6-8% growth) and non-GAAP EPS of $4.01-$4.15 (5-8% growth), reflecting continued confidence in its growth trajectory and profitability improvements.
Key Financial Metrics
Key Facts
- Fourth quarter revenue was $393.9 million, up 11% year-over-year
- Full year 2025 revenue was $1.516 billion, up 12% year-over-year
- GAAP EPS was $0.63 for Q4 (up 37% YoY) and $2.13 for full year (up 5% YoY)
- Non-GAAP EPS was $1.04 for Q4 (up 12% YoY) and $3.83 for full year (up 11% YoY)
- GAAP operating margin improved to 13.8% in Q4 (from 10.3% in prior year) and 12.2% for full year (from 11.5%)
- 2026 guidance calls for revenue of $1.610-$1.630 billion (6-8% growth) and non-GAAP EPS of $4.01-$4.15 (5-8% growth)
- Endoscopy Devices segment grew 33% year-over-year, the fastest growing segment
- Free cash flow was $215.7 million for the year, up 16% year-over-year
Financial Impact
Revenue growth of 12% and EPS growth of 5% in 2025, with guidance for 6-8% revenue growth and 5-8% EPS growth in 2026
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cardiovascular | $1.4B | +11.0% |
| Endoscopy | $72.9M | +33.0% |
Risk Factors
- Integration risks from recent acquisitions (C2 Acquisition, Biolife Merger, Cook Transaction, EGS Transaction)
- Potential impact of trade policies and tariffs from the U.S. and other countries
- Supply chain, manufacturing, or sterilization disruptions
- Fluctuations in interest or foreign currency exchange rates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (MMSI), Batch item 1 | 0000856982-26-000007 |
| Document: mmsi-20260224xex99d2.htm | 0000856982-26-000007 |
| Document: mmsi-20260224x8k.htm | 0000856982-26-000007 |
| Document: 0000856982-26-000007-index-headers.html | 0000856982-26-000007 |
| Document: 0000856982-26-000007-index.html | 0000856982-26-000007 |
| Document: 0000856982-26-000007.txt | 0000856982-26-000007 |
| 8-K Filing (MMSI), Batch item 7 | 0000856982-26-000007 |
| CONTEXT: Previous Earnings (2026-02-24) | 0000856982-26-000007 |
Track record
12 reports on MMSI
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.91% at T+60 after the May 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago Press Release Neutral 3/10 Entry $89.62 Now $86.35 −3.65% settles Feb 3
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $86.24 Now $86.35 +0.13% settles Jan 28
- Oct 29, 202618d ago Press Release Neutral 4/10 Entry $86.24 Now $86.35 +0.13% settles Jan 28
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $92.21 Now $86.35 −6.36% settles Jan 26
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $71.09 to $87.00 Now $86.35 +21.47% ▲ +22.38% +18.81% vs SPY
- May 5, 202628w ago Insider Cluster Neutral 3/10 Entry $60.44 to $83.35 Now $86.35 +42.87% ▲ +37.91% +35.17% vs SPY
- May 5, 202628w ago Insider Cluster Bullish 6/10 Entry $60.44 to $83.35 Now $86.35 +42.87% ▲ +37.91% +35.17% vs SPY
- Apr 30, 202628w ago Press Release Bullish 7/10 Entry $62.01 to $78.29 Now $86.35 +39.25% ▲ +26.25% +23.18% vs SPY
- Apr 16, 202630w ago Court Ruling Bullish 6/10 Entry $70.10 to $73.26 Now $86.35 +23.18% ▲ +4.51% −2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers